Search results
Results from the WOW.Com Content Network
For a response of 0.25a.u., Drug B is more potent, as it generates this response at a lower concentration. For a response of 0.75a.u., Drug A is more potent. a.u. refers to "arbitrary units". In pharmacology , potency or biological potency [ 1 ] is a measure of a drug's biological activity expressed in terms of the dose required to produce a ...
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]
"The Use of Medicines in the United States".IMS Institute for Healthcare Informatics.The Use of Medicines in the United States. June 2012. p. 40.
Variation in potency of certain effects may exist amongst individual benzodiazepines. Some benzodiazepines produce active metabolites . Active metabolites are produced when a person's body metabolizes the drug into compounds that share a similar pharmacological profile to the parent compound and thus are relevant when calculating how long the ...
The structure-activity relationship of the drug class has been explored to a reasonable extent. The optimal substitution pattern is fairly tightly defined (i.e. N,N-diethyl on the amine nitrogen, 4-ethoxy on the benzyl ring and 5-nitro on the benzimidazole ring), but even derivatives incorporating only some of these features are still potent opioids.
Medications, illicit drugs, and prior substance use history have also been found to affect MAC. For example, acute use of amphetamines, cocaine, ephedrine, and chronic use of alcohol increase MAC. Whereas, administration of propofol, etomidate, barbiturates, benzodiazepines, ketamine, opiates, local anesthetics, lithium, verapamil, and alpha 2 ...
The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing is a pocket-size medical manual focusing on the most commonly prescribed medicines by the British National Health Service (NHS). It was first published by Churchill Livingstone , Elsevier , in 2014, revised in a second edition in 2018, and again in 2022 in a third edition.
The ED50 is commonly used as a measure of the reasonable expectancy of a drug effect, but does not necessarily represent the dose that a clinician might use. This depends on the need for the effect, and also the toxicity. The toxicity and even the lethality of a drug can be quantified by the TD 50 and LD 50 respectively. Ideally, the effective ...